Immunology

Paper highlights preclinical results of HIV peptide vaccine

Published in Vaccine Weekly, October 29th, 2003

Generex Biotechnology Corp. (GNBT) announced publication of a scientific paper from its Antigen Express immunomedicine subsidiary reporting progress in developing a novel peptide vaccine for HIV.

The Antigen Express Ii-Key peptide technology boosts the presentation of T-helper cell-stimulating, MHC-class-II-presented peptides to the immune system. In this study, mice immunized with Ii-Key peptide hybrids of peptide epitopes from two different HIV proteins (gp160 and gag) had significantly more potent immune responses, as measured in vitro by ELISPOT analyses, than did naked MHC class II epitope-only peptides.

The paper, "Ii-Key MHC class II epitope...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-10-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry